Exherin (trifluoroacetate) manufacturers
|
| | Exherin (trifluoroacetate) Basic information |
| Product Name: | Exherin (trifluoroacetate) | | Synonyms: | ADH-1 TRIFLUOROACETATE;Exherin (trifluoroacetate);ADH-1 trifluroacetate;ADH 1,ADH1 trifluoroacetate,Inhibitor,ADH1,ADH-1,inhibit,ADH 1 trifluoroacetate;ADH-1 trifluoroacetate, 10 mM in DMSO | | CAS: | 1135237-88-5 | | MF: | C22H34N8O6S2.C2HF3O2 | | MW: | 684.71 | | EINECS: | | | Product Categories: | | | Mol File: | 1135237-88-5.mol |  |
| | Exherin (trifluoroacetate) Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO:43.0(Max Conc. mg/mL);62.8(Max Conc. mM) | | form | Solid | | color | White to off-white |
| | Exherin (trifluoroacetate) Usage And Synthesis |
| Uses | ADH-1 trifluoroacetate is an N-cadherin antagonist, which inhibits N-cadherin mediated cell adhesion. | | in vivo | ADH-1 (50 mg/kg) significantly prevents tumor growth and metastasis in a mouse model for pancreatic cancer. ADH-1 prevents tumor cell invasion and metastasis in an orthotopic model for pancreatic cancer using N-cadherin overexpressing BxPC-3 cells[1]. ADH-1, at the dosages evaluated, does not display either antiangiogenic activity in a rat aortic ring assay or antitumor potential in a PC3 subcutaneous xenograft tumor model[2]. ADH-1 (10 mL/kg, i.p.) augmentation of melanoma tumor growth is overcome through its ability to make regionally infused melphalan more effective. ADH-1 mediated augmentation of melanoma tumor growth is not altered by regionally infused temozolomide. In A375, but not DM443 xenografts, ADH-1 treatment increases phosphorylation of AKT at serine 473. ADH-1 slightly diminishes N-cadherin expression in both xenografts[3]. | | References | [1] Shintani Y, et al. ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression. Int J Cancer. 2008 Jan 1;122(1):71-7. DOI:10.1002/ijc.23027
[2] Li H, et al. ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancer. Anticancer Drugs. 2007 Jun;18(5):563-8. DOI:10.1097/CAD.0b013e328020043e
[3] Turley RS, et al. Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma. Ann Surg. 2015 Feb;261(2):368-77 DOI:10.1097/SLA.0000000000000635 |
| | Exherin (trifluoroacetate) Preparation Products And Raw materials |
|